دورية أكاديمية
Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population.
| العنوان: | Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population. |
|---|---|
| المؤلفون: | Loughman J; Centre for Eye Research Ireland, School of Physics, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland., Kobia-Acquah E; Centre for Eye Research Ireland, School of Physics, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland., Lingham G; Centre for Eye Research Ireland, School of Physics, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.; Centre for Ophthalmology and Visual Science (incorporating Lions Eye Institute), The University of Western Australia, Perth, Western Australia, Australia., Butler J; Centre for Eye Research Ireland, School of Physics, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.; School of Mathematical Sciences, Technological University Dublin, Dublin, Ireland., Loskutova E; Centre for Eye Research Ireland, School of Physics, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland., Mackey DA; Centre for Ophthalmology and Visual Science (incorporating Lions Eye Institute), The University of Western Australia, Perth, Western Australia, Australia.; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia.; School of Medicine, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia., Lee SSY; Centre for Ophthalmology and Visual Science (incorporating Lions Eye Institute), The University of Western Australia, Perth, Western Australia, Australia., Flitcroft DI; Centre for Eye Research Ireland, School of Physics, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.; Department of Ophthalmology, Children's Health Ireland at Temple Street Hospital, Dublin, Ireland. |
| المصدر: | Acta ophthalmologica [Acta Ophthalmol] 2024 May; Vol. 102 (3), pp. e245-e256. Date of Electronic Publication: 2023 Sep 11. |
| نوع المنشور: | Randomized Controlled Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101468102 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1755-3768 (Electronic) Linking ISSN: 1755375X NLM ISO Abbreviation: Acta Ophthalmol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford, UK : Wiley-Blackwell Original Publication: Oxford, UK ; Malden, MA : Blackwell Munksgaard |
| مواضيع طبية MeSH: | COVID-19*/epidemiology , Myopia*/diagnosis , Myopia*/drug therapy , Myopia*/epidemiology, Child ; Humans ; Atropine ; Axial Length, Eye ; Disease Progression ; Ophthalmic Solutions ; Refraction, Ocular ; Treatment Outcome ; Adolescent |
| مستخلص: | Purpose: The Myopia Outcome Study of Atropine in Children (MOSAIC) is an investigator-led, double-masked, randomized controlled trial investigating the efficacy and safety of 0.01% atropine eye drops for managing myopia progression in a predominantly White, European population. Methods: Children aged 6-16 years with myopia were randomly allocated 2:1 to nightly 0.01% atropine or placebo eye drops in both eyes for 2 years. The primary outcome was cycloplegic spherical equivalent (SE) progression at 24 months. Secondary outcomes included axial length (AL) change, safety and acceptability. Linear mixed models with random intercepts were used for statistical analyses. Results: Of 250 participants enrolled, 204 (81.6%) completed the 24-month visit (136 (81.4%) treatment, 68 (81.9%) placebo). Baseline characteristics, drop-out and adverse event rates were similar between treatment and control groups. At 24 months, SE change was not significantly different between 0.01% atropine and placebo groups (effect = 0.10 D, p = 0.07), but AL growth was lower in the 0.01% atropine group, compared to the placebo group (-0.07 mm, p = 0.007). Significant treatment effects on SE (0.14 D, p = 0.049) and AL (-0.11 mm, p = 0.002) were observed in children of White, but not non-White (SE = 0.05 D, p = 0.89; AL = 0.008 mm, p = 0.93), ethnicity at 24 months. A larger treatment effect was observed in subjects least affected by COVID-19 restrictions (SE difference = 0.37 D, p = 0.005; AL difference = -0.17 mm, p = 0.001). Conclusions: Atropine 0.01% was safe, well-tolerated and effective in slowing axial elongation in this European population. Treatment efficacy varied by ethnicity and eye colour, and potentially by degree of COVID-19 public health restriction exposure during trial participation. (© 2023 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.) |
| References: | Armstrong, R.A. (2017) Recommendations for analysis of repeated‐measures designs: testing and correcting for sphericity and use of manova and mixed model analysis. Ophthalmic and Physiological Optics, 37, 585–593. Azuara‐Blanco, A., Logan, N., Strang, N., Saunders, K., Allen, P., Weir, R. et al. (2020) Low‐dose (0.01%) atropine eye‐drops to reduce progression of myopia in children: a multicentre placebo‐controlled randomised trial in the UK (CHAMP‐UK)—study protocol. British Journal of Ophthalmology, 104, 950–955. Brennan, N.A., Toubouti, Y.M., Cheng, X. & Bullimore, M.A. (2021) Efficacy in myopia control. Progress in Retinal and Eye Research, 83, 100923. Central Statistics Office. (2017) Census of population 2016—profile 8 Irish travellers, ethnicity and religion. Chia, A., Chua, W.H., Cheung, Y.B., Wong, W.L., Lingham, A., Fong, A. et al. (2012) Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology, 119, 347–354. Chia, A., Lu, Q. & Tan, D. (2016) Five‐year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology, 123, 391–399. Chua, W.H., Balakrishnan, V., Chan, Y.H., Tong, L., Ling, Y., Quah, B.L. et al. (2006) Atropine for the treatment of childhood myopia. Ophthalmology, 113, 2285–2291. Erdinest, N., London, N., Levinger, N., Lavy, I., Pras, E. & Morad, Y. (2022) Decreased effectiveness of 0.01% atropine treatment for myopia control during prolonged COVID‐19 lockdowns. Contact Lens & Anterior Eye, 45, 101475. Gong, Q., Janowski, M., Luo, M., Wei, H., Chen, B., Yang, G. et al. (2017) Efficacy and adverse effects of atropine in childhood myopia: a meta‐analysis. JAMA Ophthalmology, 135, 624–630. Grzybowski, A., Kanclerz, P., Tsubota, K., Lanca, C. & Saw, S.M. (2020) A review on the epidemiology of myopia in school children worldwide. BMC Ophthalmology, 20, 1–11. Harrington, S.C., Stack, J., Saunders, K. & O'Dwyer, V. (2019) Refractive error and visual impairment in Ireland schoolchildren. British Journal of Ophthalmology, 103, 1112–1118. Hieda, O., Hiraoka, T., Fujikado, T., Ishiko, S., Hasebe, S., Torii, H. et al. (2021) Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2‐year randomized placebo‐controlled study. Japanese Journal of Ophthalmology, 65, 315–325. Holmes, J.M., Strauber, S., Quinn, G.E., Cole, S.R., Felius, J. & Kulp, M. (2008) Further validation of the amblyopia treatment index parental questionnaire. Journal of American Association for Pediatric Ophthalmology and Strabismus, 12, 581–584. Huang, J., Wen, D., Wang, Q., McAlinden, C., Flitcroft, I., Chen, H. et al. (2016) Efficacy comparison of 16 interventions for myopia control in children: a network meta‐analysis. Ophthalmology, 123, 697–708. Hyman, L., Gwiazda, J., Hussein, M., Norton, T.T., Wang, Y., Marsh‐Tootle, W. et al. (2005) Relationship of age, sex, and ethnicity with myopia progression and axial elongation in the correction of myopia evaluation trial. Archives of Ophthalmology, 123, 977–987. Jones‐Jordan, L.A., Sinnott, L.T., Chu, R.H., Cotter, S.A., Kleinstein, R.N., Manny, R.E. et al. (2021) Myopia progression as a function of sex, age, and ethnicity. Investigative Ophthalmology and Visual Science, 62, 36. Kaphle, D., Atchison, D. & Schmid, K. (2020) Multifocal spectacles in childhood myopia: are treatment effects maintained? A systematic review and meta‐analysis. Survey of Ophthalmology, 65, 239–249. Lee, S.S.Y., Lingham, G., Blaszkowska, M., Sanfilippo, P.G., Koay, A., Franchina, M. et al. (2022) Low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of Australian children: a randomised clinical trial. Clinical & Experimental Ophthalmology, 50, 1001–1012. Lingham, G., Kobia‐Acquah, E., Loughman, J. & Flitcroft, D.I. (2022) Repository: MOSAIC clinical trial statistical analysis plan primary analysis v1.2. ARROW@TU Dublin. https://arrow.tudublin.ie/ceyoth/3/. Loughman, J. & Flitcroft, D.I. (2016) The acceptability and visual impact of 0.01% atropine in a Caucasian population. British Journal of Ophthalmology, 100, 1525–1529. Mackey, D.A., Wilkinson, C.H., Kearns, L.S. & Hewitt, A.W. (2011) Classification of iris colour: review and refinement of a classification schema. Clinical & Experimental Ophthalmology, 39, 462–471. McCrann, S., Flitcroft, I., Strang, N., Saunders, K., Logan, N., Lee, S. et al. (2019) Myopia outcome study of atropine in children (MOSAIC): an investigator‐led, double‐masked, placebo‐controlled, randomised clinical trial protocol. HRB Open Research, 2, 15. McCullough, S., Adamson, G., Breslin, K.M.M., McClelland, J.F., Doyle, L. & Saunders, K.J. (2020) Axial growth and refractive change in white European children and young adults: predictive factors for myopia. Scientific Reports, 10, 15189. Nash, R., Bunce, C., Freemantle, N., Doré, C. & Rogers, C. (2014) Ophthalmic statistics note 4: analysing data from randomised controlled trials with baseline and follow‐up measurements. British Journal of Ophthalmology, 98, 1467–1469. O'Donoghue, L., McClelland, J.F., Logan, N.S., Rudnicka, A.R., Owen, C.G. & Saunders, K.J. (2010) Refractive error and visual impairment in school children in Northern Ireland. British Journal of Ophthalmology, 94, 1155–1159. Repka, M.X., Weise, K.K., Chandler, D.L., Wu, R., Melia, B.M., Manny, R.E. et al. (2023) Low‐dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmology, 141, 756–765. Rudnicka, A., Kapetanakis, V., Wathern, A., Logan, N., Gilmartin, B., Whincup, P. et al. (2016) Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta‐analysis: implications for aetiology and early prevention. British Journal of Ophthalmology, 100, 882–890. Saxena, R., Dhiman, R., Gupta, V., Kumar, P., Matalia, J., Roy, L. et al. (2021) Atropine for the treatment of childhood myopia in India: multicentric randomized trial. Ophthalmology, 128, 1367–1369. Tsai, H.R., Wang, J.H., Huang, H.K., Chen, T.L., Chen, P.W. & Chiu, C.J. (2022) Efficacy of atropine, orthokeratology, and combined atropine with orthokeratology for childhood myopia: a systematic review and network meta‐analysis. Journal of the Formosan Medical Association, 121, 2490–2500. Available from: https://doi.org/10.1016/J.JFMA.2022.05.005. Vitale, S., Sperduto, R.D. & Ferris, F.L. (2009) Increased prevalence of myopia in the United States between 1971–1972 and 1999–2004. Archives of Ophthalmology, 127, 1632–1639. Walline, J.J., Lindsley, K.B., Vedula, S.S., Cotter, S.A., Mutti, D.O., Ng, S.M. et al. (2020) Interventions to slow progression of myopia in children. Cochrane Database of Systematic Reviews, 1(1), CD004916. Wang, J., Li, Y., Musch, D.C., Wei, N., Qi, X., Ding, G. et al. (2021) Progression of myopia in school‐aged children after COVID‐19 home confinement. JAMA Ophthalmology, 139, 293–300. Wang, Y.R., Bian, H.L. & Wang, Q. (2017) Atropine 0.5% eyedrops for the treatment of children with low myopia: a randomized controlled trial. Medicine, 96(27), e7371. Wei, S., Li, S.M., An, W., Du, J., Liang, X., Sun, Y. et al. (2020) Safety and efficacy of low‐dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial. JAMA Ophthalmology, 138, 1178–1184. Williams, K.M., Bertelsen, G., Cumberland, P., Wolfram, C., Verhoeven, V.J.M., Anastasopoulos, E. et al. (2015) Increasing prevalence of myopia in Europe and the impact of education. Ophthalmology, 122, 1489–1497. Williams, K.M., Verhoeven, V.J.M., Cumberland, P., Bertelsen, G., Wolfram, C., Buitendijk, G.H.S. et al. (2015) Prevalence of refractive error in Europe: the European eye epidemiology (E3) consortium. European Journal of Epidemiology, 30, 305–315. Yam, J.C., Jiang, Y., Tang, S.M., Law, A.K.P., Chan, J.J., Wong, E. et al. (2019) Low‐concentration atropine for myopia progression (LAMP) study: a randomized, double‐blinded, placebo‐controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology, 126, 113–124. Yam, J.C., Li, F.F., Zhang, X., Tang, S.M., Yip, B.H.K., Kam, K.W. et al. (2020) Two‐year clinical trial of the low‐concentration atropine for myopia progression (LAMP) study: phase 2 report. Ophthalmology, 127, 910–919. Yam, J.C., Zhang, X., Zhang, Y., Yip, B., Tang, F., Wong, E. et al. (2023) Effect of low‐concentration atropine eyedrops vs placebo on myopia incidence in children: the LAMP2 randomized clinical trial. JAMA, 329, 472–481. Yam, J.C., Zhang, X.J., Zhang, Y., Wang, Y.M., Tang, S.M., Li, F.F. et al. (2022) Three‐year clinical trial of low‐concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report. Ophthalmology, 129, 308–321. Yi, S., Huang, Y., Yu, S.Z., Chen, X.J., Yi, H. & Zeng, X.L. (2015) Therapeutic effect of atropine 1% in children with low myopia. Journal of American Association for Pediatric Ophthalmology and Strabismus, 19, 426–429. Yum, H.R., Park, S.H. & Shin, S.Y. (2021) Influence of coronavirus disease 2019 on myopic progression in children treated with low‐concentration atropine. PLoS One, 16(2021), e0257480. Zadnik, K., Schulman, E., Flitcroft, I., Fogt, J.S., Blumenfeld, L.C., Fong, T.M. et al. (2023) Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmology, e232097. Available from: https://doi.org/10.1001/jamaophthalmol.2023.2097. |
| معلومات مُعتمدة: | MRCG 2016-13 Fighting Blindness Ireland; Health Research Board Ireland |
| فهرسة مساهمة: | Keywords: Europe; atropine; children; myopia; myopia control |
| المشرفين على المادة: | 7C0697DR9I (Atropine) 0 (Ophthalmic Solutions) |
| تواريخ الأحداث: | Date Created: 20230911 Date Completed: 20240410 Latest Revision: 20240429 |
| رمز التحديث: | 20240429 |
| DOI: | 10.1111/aos.15761 |
| PMID: | 37694816 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1755-3768 |
|---|---|
| DOI: | 10.1111/aos.15761 |